Meeting
2022 ASCO Annual Meeting
A phase II, single-arm, non-randomized study of alpelisib (BYL719) in combination with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (btcrc-BRE19-409).
Authors
Cristina I. Truica
Penn State Health Milton S. Hershey Medical Center, Hershey, PA
Cristina I. Truica , Amanda Marie Parkes , Oana Cristina Danciu , Monali K. Vasekar , Kent Hoskins , Kari Braun Wisinski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04762979
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS1114)
DOI
10.1200/JCO.2022.40.16_suppl.TPS1114
Abstract #
TPS1114
Poster Bd #
487b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Detection of actionable gene mutations in breast cancer by amplicon-based next-generation sequencing liquid biopsy.
First Author: Jing Shan Lim
Poster
2017 ASCO Annual Meeting
A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1.
First Author: Hope S. Rugo
Poster
2016 ASCO Annual Meeting
SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.
First Author: Fabrice Andre
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz